Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0000912282-10-000338
Filing Date
2010-03-15
Accepted
2010-03-15 17:20:52
Documents
12
Period of Report
2009-12-31

Document Format Files

Seq Description Document Type Size
1 oncolytics-20f_123109.htm 20-F 1313007
2 GRAPHIC img1.gif GRAPHIC 4606
3 GRAPHIC img2.jpg GRAPHIC 16971
4 LIST OF SUBSIDIARIES ex8_0.htm EX-8.0 3952
5 302 CERT CEO ex12_1.htm EX-12.1 10735
6 302 CERT CFO ex12_2.htm EX-12.2 10718
7 906 CERT CEO ex13_1.htm EX-13.1 5953
8 906 CERT CFO ex13_2.htm EX-13.2 5915
9 AUDITED ANNUAL CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 2 ex99_1.htm EX-99.1 675499
10 GRAPHIC ey_sig.jpg GRAPHIC 2342
11 MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE YEARS ENDED DECEMBER 31, 2009, 200 ex99_2.htm EX-99.2 428787
12 GRAPHIC logo.gif GRAPHIC 8844
  Complete submission text file 0000912282-10-000338.txt   2501664
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 000-31062 | Film No.: 10682586
SIC: 2834 Pharmaceutical Preparations